

Listing of Claims:

Claims 1-7 (canceled).

8. (presently amended) An isolated FGF homolog polypeptide selected from the group consisting of:

a) polypeptide molecules comprising an amino acid sequence as shown in comprising SEQ ID NO: 2 from residue 28 (Glu) to residue 175 (Met);

and

b) polypeptide molecules that are at least 80% identical to SEQ ID NO: 2 from amino acid residue 28 (Glu) to amino acid residue 175 (Met)

wherein said polypeptide bind to an FGF receptor or is capable of stimulating proliferation of cells derived from mesenchymal stem cells or their precursors.

9. (presently amended) An isolated FGF homolog polypeptide selected from the group consisting of:

a) polypeptide molecules comprising an amino acid sequence as shown in comprising SEQ ID NO: 2 from residue 28 (Glu) to residue 196 (Lys);

and

b) polypeptide molecules that are at least 80% identical to SEQ ID NO: 2 from amino acid residue 28 (Glu) to amino acid residue 196 (Lys)

wherein said polypeptide binds to an FGF receptor or is capable of stimulating proliferation of cells derived from mesenchymal stem cells or their precursors.

10. (presently amended) An isolated FGF homolog polypeptide selected from the group consisting of:

a) polypeptide molecules comprising an amino acid sequence as shown in comprising SEQ ID NO: 2 from residue 28 (Glu) to residue 207 (Ala);

and

b) polypeptide molecules that are at least 80% identical to the amino acids of SEQ ID NO: 2 from amino acid residue 28 (Glu) to amino acid residue 207 (Ala)

wherein said polypeptide binds to an FGF receptor or is capable of stimulating proliferation of cells derived from mesenchymal stem cells or their precursors.

11. (original) The FGF homolog polypeptide of claim 8 further comprising a signal sequence.

12. (original) The FGF homolog polypeptide of claim 8 further comprising a signal sequence ~~as shown in~~ comprising SEQ ID NO: 2 from amino acid residue 1 (Met) to amino acid residue 27 (Ala).

13. (original) A pharmaceutical composition comprising a purified FGF homolog polypeptide according to claim 8, in combination with a pharmaceutically acceptable vehicle.

Claims 14-20 (canceled).

21. (previously presented) An isolated FGF homolog polypeptide of claim 8 wherein said polypeptide is at least 90% identical to SEQ ID NO: 2 from amino acid residue 28 (Glu) to amino acid residue 175 (Met).

22. (previously presented) An isolated FGF homolog polypeptide of claim 8 wherein said polypeptide is at least 95% identical to SEQ ID NO: 2 from amino acid residue 28 (Glu) to amino acid residue 175 (Met).

23. (previously presented) An isolated FGF homolog polypeptide of claim 8 wherein said polypeptide is at least 90% identical to SEQ ID NO: 2 from amino acid residue 28 (Glu) to amino acid residue 196 (Lys).

24. (previously presented) An isolated FGF homolog polypeptide of claim 8 wherein said polypeptide is at least 95% identical to SEQ ID NO: 2 from amino acid residue 28 (Glu) to amino acid residue 196 (Lys).

25. (previously presented) An isolated FGF homolog polypeptide of claim 8 wherein said polypeptide is at least 90% identical to SEQ ID NO: 2 from amino acid residue 28 (Glu) to amino acid residue 207 (Ala).

26. (previously presented) An isolated FGF homolog polypeptide of claim 8 wherein said polypeptide is at least 95% identical to SEQ ID NO: 2 from amino acid residue 28 (Glu) to amino acid residue 207 (Ala).

27. (previously presented) The FGF homolog polypeptide of claim 9 further comprising a signal sequence.

28. (presently amended) The FGF homolog polypeptide of claim 9 further comprising a signal sequence as shown in comprising SEQ ID NO: 2 from amino acid residue 1 (Met) to amino acid residue 27 (Ala).

29. (previously presented) A pharmaceutical composition comprising a purified FGF homolog polypeptide according to claim 9, in combination with a pharmaceutically acceptable vehicle.

30. (previously presented) The FGF homolog polypeptide of claim 10 further comprising a signal sequence.

31. (presently amended) The FGF homolog polypeptide of claim 10 further comprising a signal sequence as shown in comprising SEQ ID NO: 2 from amino acid residue 1 (Met) to amino acid residue 27 (Ala).

32. (previously presented) A pharmaceutical composition comprising a purified FGF homolog polypeptide according to claim 10, in combination with a pharmaceutically acceptable vehicle.

33. (presently amended) An isolated FGF homolog polypeptide selected from the group consisting of:

- a) fragments of polypeptide molecules comprising an amino acid sequence as shown in comprising SEQ ID NO: 2 from residue 58 (Tyr) 28 (Gly) to residue 175 (Met);
and
b) polypeptide molecules that are at least 80% identical to SEQ ID NO: 2 from amino acid residue 58 (Tyr) to amino acid residue 175 (Met) the fragment of a)

wherein said polypeptide fragment binds to an FGF receptor or is capable of stimulating proliferation of cells derived from mesenchymal stem cells or their precursors.

34. (presently amended) An isolated FGF homolog polypeptide selected from the group consisting of:

a) fragments of polypeptide molecules comprising an amino acid sequence ~~as shown in~~ comprising SEQ ID NO: 2 from residue 58 (Tyr) 28 (Gly) to residue 196 (Lys);

and

b) polypeptide molecules that are at least 80% identical to ~~SEQ ID NO: 2 from amino acid residue 58 (Tyr) to amino acid residue 196 (Lys)~~ the fragment of a)

wherein said polypeptide fragment binds to an FGF receptor or is capable of stimulating proliferation of cells derived from mesenchymal stem cells or their precursors.

35. (presently amended) An isolated FGF homolog polypeptide selected from the group consisting of:

a) fragments of polypeptide molecules comprising an amino acid sequence ~~as shown in~~ comprising SEQ ID NO: 2 from residue 58 (Tyr) 28 (Gly) to residue 207 (Ala);

and

b) polypeptide molecules that are at least 80% identical to ~~the amino acids of SEQ ID NO: 2 from amino acid residue 58 (Tyr) to amino acid residue 207 (Ala)~~ the fragment of a)

wherein said polypeptide fragment binds to an FGF receptor or is capable of stimulating proliferation of cells derived from mesenchymal stem cells or their precursors.